Skip to main content

Advertisement

SpringerLink
Log in

Evaluating DAPK as a therapeutic target

  • The Universe of DAPK
  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

Death associated protein kinase 1 (DAPK) is an important serine/theoreine kinase involved in various cellular processes such as apoptosis, autophagy and inflammation. DAPK expression and activity are misregulated in multiple diseases including cancer, neuronal death, stoke, et al. Methylation of the DAPK gene is common in many types of cancer and can lead to loss of DAPK expression. In this review, we summarize the pathological status and functional roles of DAPK in disease and compare the published reagents that can manipulate the expression or activity of DAPK. The pleiotropic functions of DAPK make it an intriguing target and the barriers and opportunities for targeting DAPK for future clinical application are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chen XP, Du GH (2007) Target validation: a door to drug discovery. Drug Discov Ther 1(1):23–29

    CAS  PubMed  Google Scholar 

  2. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5(12):993–996

    CAS  PubMed  Google Scholar 

  3. Pennisi E (2012) Genomics. ENCODE project writes eulogy for junk DNA. Science 337(6099):1159–1161

    CAS  PubMed  Google Scholar 

  4. Baker NM, Der CJ (2013) Cancer: drug for an ‘undruggable’ protein. Nature 497(7451):577–578

    CAS  PubMed  Google Scholar 

  5. Bialik S, Kimchi A (2006) The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem 75:189–210

    CAS  PubMed  Google Scholar 

  6. Michie AM, McCaig AM, Nakagawa R, Vukovic M (2010) Death-associated protein kinase (DAPK) and signal transduction: regulation in cancer. FEBS J 277(1):74–80

    CAS  PubMed  Google Scholar 

  7. Tu W, Xu X, Peng L, Zhong X, Zhang W, Soundarapandian MM, Balel C, Wang M, Jia N, Lew F, Chan SL, Chen Y, Lu Y (2010) DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell 140(2):222–234

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Chakilam S, Gandesiri M, Rau TT, Agaimy A, Vijayalakshmi M, Ivanovska J, Wirtz RM, Schulze-Luehrmann J, Benderska N, Wittkopf N, Chellappan A, Ruemmele P, Vieth M, Rave-Frank M, Christiansen H, Hartmann A, Neufert C, Atreya R, Becker C, Steinberg P, Schneider-Stock R (2013) Death-associated protein kinase controls STAT3 activity in intestinal epithelial cells. Am J Pathol 182(3):1005–1020

    CAS  PubMed  Google Scholar 

  9. Nakav S, Cohen S, Feigelson SW, Bialik S, Shoseyov D, Kimchi A, Alon R (2012) Tumor suppressor death-associated protein kinase attenuates inflammatory responses in the lung. Am J Respir Cell Mol Biol 46(3):313–322

    CAS  PubMed  Google Scholar 

  10. Luo XJ, Li W, Yang LF, Yu XF, Xiao LB, Tang M, Dong X, Deng QP, Bode AM, Liu JK, Cao Y (2011) DAPK1 mediates the G1 phase arrest in human nasopharyngeal carcinoma cells induced by grifolin, a potential antitumor natural product. Eur J Pharmacol 670(2–3):427–434

    CAS  PubMed  Google Scholar 

  11. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A (1995) Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 9(1):15–30

    CAS  PubMed  Google Scholar 

  12. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, Kimchi A (1997) DAP kinase links the control of apoptosis to metastasis. Nature 390(6656):180–184

    CAS  PubMed  Google Scholar 

  13. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A (2001) DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3(1):1–7

    CAS  PubMed  Google Scholar 

  14. Bialik S, Kimchi A (2004) DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death. Semin Cancer Biol 14(4):283–294

    CAS  PubMed  Google Scholar 

  15. Wang WJ, Kuo JC, Yao CC, Chen RH (2002) DAP-kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals. J Cell Biol 159(1):169–179

    CAS  PubMed  Google Scholar 

  16. Kuo JC, Wang WJ, Yao CC, Wu PR, Chen RH (2006) The tumor suppressor DAPK inhibits cell motility by blocking the integrin-mediated polarity pathway. J cell biol 172(4):619–631

    CAS  PubMed  Google Scholar 

  17. Mor I, Carlessi R, Ast T, Feinstein E, Kimchi A (2012) Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase. Oncogene 31(6):683–693

    CAS  PubMed  Google Scholar 

  18. Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2(1):a001008

    PubMed  Google Scholar 

  19. Katzenellenbogen RA, Baylin SB, Herman JG (1999) Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93(12):4347–4353

    CAS  PubMed  Google Scholar 

  20. Simpson DJ, Clayton RN, Farrell WE (2002) Preferential loss of death associated protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene 21(8):1217–1224

    CAS  PubMed  Google Scholar 

  21. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Tamiya S, Iwamoto Y, Tsuneyoshi M (2004) Death-associated protein kinase (DAP kinase) alteration in soft tissue leiomyosarcoma: promoter methylation or homozygous deletion is associated with a loss of DAP kinase expression. Hum Pathol 35(10):1266–1271

    CAS  PubMed  Google Scholar 

  22. Toyooka S, Toyooka KO, Miyajima K, Reddy JL, Toyota M, Sathyanarayana UG, Padar A, Tockman MS, Lam S, Shivapurkar N, Gazdar AF (2003) Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res 9(8):3034–3041

    CAS  PubMed  Google Scholar 

  23. Jin Y, Blue EK, Dixon S, Hou L, Wysolmerski RB, Gallagher PJ (2001) Identification of a new form of death-associated protein kinase that promotes cell survival. J Biol Chem 276(43):39667–39678

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Lin Y, Stevens C, Harrison B, Pathuri S, Amin E, Hupp TR (2009) The alternative splice variant of DAPK-1, s-DAPK-1, induces proteasome-independent DAPK-1 destabilization. Mol Cell Biochem 328(1–2):101–107

    CAS  PubMed  Google Scholar 

  25. Khoury MP, Bourdon JC (2011) p53 Isoforms: an intracellular microprocessor? Genes Cancer 2(4):453–465

    CAS  PubMed Central  PubMed  Google Scholar 

  26. Stevens C, Lin Y, Harrison B, Burch L, Ridgway RA, Sansom O, Hupp T (2009) Peptide combinatorial libraries identify TSC2 as a death-associated protein kinase (DAPK) death domain-binding protein and reveal a stimulatory role for DAPK in mTORC1 signaling. J Biol Chem 284(1):334–344

    CAS  PubMed  Google Scholar 

  27. Tanaka T, Bai T, Yukawa K (2010) Death-associated protein kinase is essential for the survival of various types of uterine cancer cells. Int J Oncol 37(4):1017–1022

    CAS  PubMed  Google Scholar 

  28. Tanaka T, Bai T, Yukawa K (2010) Suppressed protein expression of the death-associated protein kinase enhances 5-fluorouracil-sensitivity but not etoposide-sensitivity in human endometrial adenocarcinoma cells. Oncol Rep 24(5):1401–1405

    CAS  PubMed  Google Scholar 

  29. Tanaka T, Bai T, Yukawa K (2011) Specific downregulation of death-associated protein kinase enhances Fas-mediated apoptosis in the human differentiated endometrial adenocarcinoma cell line HHUA. Eur J Gynaecol Oncol 32(3):293–296

    CAS  PubMed  Google Scholar 

  30. Henshall DC, Araki T, Schindler CK, Shinoda S, Lan JQ, Simon RP (2003) Expression of death-associated protein kinase and recruitment to the tumor necrosis factor signaling pathway following brief seizures. J Neurochem 86(5):1260–1270

    CAS  PubMed  Google Scholar 

  31. Schumacher AM, Velentza AV, Watterson DM, Wainwright MS (2002) DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury. Biochim Biophys Acta 1600(1–2):128–137

    CAS  PubMed  Google Scholar 

  32. Shamloo M, Soriano L, Wieloch T, Nikolich K, Urfer R, Oksenberg D (2005) Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia. J Biol Chem 280(51):42290–42299

    CAS  PubMed  Google Scholar 

  33. Pelled D, Raveh T, Riebeling C, Fridkin M, Berissi H, Futerman AH, Kimchi A (2002) Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons. J Biol Chem 277(3):1957–1961

    CAS  PubMed  Google Scholar 

  34. Yamamoto M, Hioki T, Ishii T, Nakajima-Iijima S, Uchino S (2002) DAP kinase activity is critical for C(2)-ceramide-induced apoptosis in PC12 cells. Eur J Biochem 269(1):139–147

    CAS  PubMed  Google Scholar 

  35. Henshall DC, Schindler CK, So NK, Lan JQ, Meller R, Simon RP (2004) Death-associated protein kinase expression in human temporal lobe epilepsy. Ann Neurol 55(4):485–494

    CAS  PubMed  Google Scholar 

  36. Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JS, Smemo S, Hinrichs A, Tacey K, Toombs TA, Kwok S, Catanese J, White TJ, Maxwell TJ, Hollingworth P, Abraham R, Rubinsztein DC, Brayne C, De Wavrant Vrieze F, Hardy J, O’Donovan M, Lovestone S, Morris JC, Thal LJ, Owen M, Williams J, Goate A (2006) DAPK1 variants are associated with Alzheimer’s disease and allele-specific expression. Hum Mol Genet 15(17):2560–2568

    CAS  PubMed  Google Scholar 

  37. Wu ZC, Zhang W, Yu JT, Zhang Q, Tian Y, Lu RC, Yu NN, Chi ZF, Tan L (2011) Association of DAPK1 genetic variations with Alzheimer’s disease in Han Chinese. Brain Res 1374:129–133

    CAS  PubMed  Google Scholar 

  38. Minster RL, DeKosky ST, Kamboh MI (2009) No association of DAPK1 and ABCA2 SNPs on chromosome 9 with Alzheimer’s disease. Neurobiol Aging 30(11):1890–1891

    CAS  PubMed Central  PubMed  Google Scholar 

  39. Schjeide BM, McQueen MB, Mullin K, DiVito J, Hogan MF, Parkinson M, Hooli B, Lange C, Blacker D, Tanzi RE, Bertram L (2009) Assessment of Alzheimer’s disease case-control associations using family-based methods. Neurogenetics 10(1):19–25

    PubMed Central  PubMed  Google Scholar 

  40. Tedde A, Piaceri I, Bagnoli S, Lucenteforte E, Piacentini S, Sorbi S, Nacmias B (2012) DAPK1 is associated with FTD and not with Alzheimer’s disease. J Alzheimer’s Dis 32(1):13–17

    CAS  Google Scholar 

  41. Hainsworth AH, Allsopp RC, Jim A, Potter JF, Lowe J, Talbot CJ, Prettyman RJ (2010) Death-associated protein kinase (DAPK1) in cerebral cortex of late-onset Alzheimer’s disease patients and aged controls. Neuropathol Appl Neurobiol 36(1):17–24

    CAS  PubMed  Google Scholar 

  42. Dachsel JC, Wider C, Vilarino-Guell C, Aasly JO, Rajput A, Rajput AH, Lynch T, Craig D, Krygowska-Wajs A, Jasinska-Myga B, Opala G, Barcikowska M, Czyzewski K, Wu RM, Heckman MG, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA (2011) Death-associated protein kinase 1 variation and Parkinson’s disease. Eur J Neurol 18(8):1090–1093

    CAS  PubMed  Google Scholar 

  43. Yamamoto M, Takahashi H, Nakamura T, Hioki T, Nagayama S, Ooashi N, Sun X, Ishii T, Kudo Y, Nakajima-Iijima S, Kimchi A, Uchino S (1999) Developmental changes in distribution of death-associated protein kinase mRNAs. J Neurosci Res 58(5):674–683

    CAS  PubMed  Google Scholar 

  44. Chuang YT, Lin YC, Lin KH, Chou TF, Kuo WC, Yang KT, Wu PR, Chen RH, Kimchi A, Lai MZ (2011) Tumor suppressor death-associated protein kinase is required for full IL-1beta production. Blood 117(3):960–970

    CAS  PubMed  Google Scholar 

  45. Mukhopadhyay R, Ray PS, Arif A, Brady AK, Kinter M, Fox PL (2008) DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating inflammatory gene expression. Mol Cell 32(3):371–382

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Chuang YT, Fang LW, Lin-Feng MH, Chen RH, Lai MZ (2008) The tumor suppressor death-associated protein kinase targets to TCR-stimulated NF-kappa B activation. J Immunol 180(5):3238–3249

    CAS  PubMed  Google Scholar 

  47. Kuester D, Guenther T, Biesold S, Hartmann A, Bataille F, Ruemmele P, Peters B, Meyer F, Schubert D, Bohr UR, Malfertheiner P, Lippert H, Silver AR, Roessner A, Schneider-Stock R (2010) Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma. Pathol Res Pract 206(9):616–624

    CAS  PubMed  Google Scholar 

  48. Gandesiri M, Chakilam S, Ivanovska J, Benderska N, Ocker M, Di Fazio P, Feoktistova M, Gali-Muhtasib H, Rave-Frank M, Prante O, Christiansen H, Leverkus M, Hartmann A, Schneider-Stock R (2012) DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions. Apoptosis 17(12):1300–1315

    CAS  PubMed  Google Scholar 

  49. Martinet W, Schrijvers DM, De Meyer GR, Thielemans J, Knaapen MW, Herman AG, Kockx MM (2002) Gene expression profiling of apoptosis-related genes in human atherosclerosis: upregulation of death-associated protein kinase. Arterioscler Thromb Vasc Biol 22(12):2023–2029

    CAS  PubMed  Google Scholar 

  50. Rennier K, Ji JY (2012) Shear stress regulates expression of death-associated protein kinase in suppressing TNFalpha-induced endothelial apoptosis. J Cell Physiol 227(6):2398–2411

    CAS  PubMed  Google Scholar 

  51. Rennier K, Ji JY (2013) Effect of shear stress and substrate on endothelial DAPK expression, caspase activity, and apoptosis. BMC Res Notes 6:10

    PubMed Central  PubMed  Google Scholar 

  52. Okamoto M, Takayama K, Shimizu T, Ishida K, Takahashi O, Furuya T (2009) Identification of death-associated protein kinases inhibitors using structure-based virtual screening. J Med Chem 52(22):7323–7327

    CAS  PubMed  Google Scholar 

  53. Okamoto M, Takayama K, Shimizu T, Muroya A, Furuya T (2010) Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening. Bioorg Med Chem 18(7):2728–2734

    CAS  PubMed  Google Scholar 

  54. Velentza AV, Wainwright MS, Zasadzki M, Mirzoeva S, Schumacher AM, Haiech J, Focia PJ, Egli M, Watterson DM (2003) An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury. Bioorg Med Chem Lett 13(20):3465–3470

    CAS  PubMed  Google Scholar 

  55. Cho EY, Lee SJ, Nam KW, Shin J, Oh KB, Kim KH, Mar W (2010) Amelioration of oxygen and glucose deprivation-induced neuronal death by chloroform fraction of bay leaves (Laurus nobilis). Biosci Biotechnol Biochem 74(10):2029–2035

    CAS  PubMed  Google Scholar 

  56. Wu B, Yao H, Wang S, Xu R (2013) DAPK1 modulates a curcumin-induced G2/M arrest and apoptosis by regulating STAT3, NF-kappaB, and caspase-3 activation. Biochem Biophys Res Commun 434(1):75–80

    CAS  PubMed  Google Scholar 

  57. Carlessi R, Levin-Salomon V, Ciprut S, Bialik S, Berissi H, Albeck S, Peleg Y, Kimchi A (2011) GTP binding to the ROC domain of DAP-kinase regulates its function through intramolecular signalling. EMBO Rep 12(9):917–923

    CAS  PubMed Central  PubMed  Google Scholar 

  58. Lin Y, Henderson P, Pettersson S, Satsangi J, Hupp T, Stevens C (2011) Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway. FEBS J 278(2):354–370

    CAS  PubMed  Google Scholar 

  59. Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9(5):277–291

    CAS  PubMed  Google Scholar 

  60. Kay MA (2011) State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 12(5):316–328

    CAS  PubMed  Google Scholar 

  61. Nair SB, Fayaz SM, Rajanikant GK (2013) A novel multi-target drug screening strategy directed against key proteins of DAPK family. Comb Chem High Throughput Screen 16(6):449–457

    CAS  PubMed  Google Scholar 

  62. Harrington JA, Wheeler GM, Sweeting MJ, Mander AP, Jodrell DI (2013) Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol 10(5):277–288

    CAS  PubMed  Google Scholar 

  63. Cohen O, Inbal B, Kissil JL, Raveh T, Berissi H, Spivak-Kroizaman T, Feinstein E, Kimchi A (1999) DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 146(1):141–148

    CAS  PubMed  Google Scholar 

  64. Lin Y, Stevens C, Hupp T (2007) Identification of a dominant negative functional domain on DAPK-1 that degrades DAPK-1 protein and stimulates TNFR-1-mediated apoptosis. J biol chem 282(23):16792–16802

    CAS  PubMed  Google Scholar 

  65. Jin Y, Blue EK, Gallagher PJ (2006) Control of death-associated protein kinase (DAPK) activity by phosphorylation and proteasomal degradation. J biol chem 281(51):39033–39040

    CAS  PubMed Central  PubMed  Google Scholar 

  66. Jin Y, Blue EK, Dixon S, Shao Z, Gallagher PJ (2002) A death-associated protein kinase (DAPK)-interacting protein, DIP-1, is an E3 ubiquitin ligase that promotes tumor necrosis factor-induced apoptosis and regulates the cellular levels of DAPK. J biol chem 277(49):46980–46986

    CAS  PubMed Central  PubMed  Google Scholar 

  67. Lane DP, Cheok CF, Lain S (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2(9):a001222

    PubMed  Google Scholar 

  68. Mandl A, Huong Pham L, Toth K, Zambetti G, Erhardt P (2011) Puma deletion delays cardiac dysfunction in murine heart failure models through attenuation of apoptosis. Circulation 124(1):31–39

    CAS  PubMed  Google Scholar 

  69. Takeuchi S, Matsushita M, Zimmermann M, Ikezoe T, Komatsu N, Seriu T, Schrappe M, Bartram CR, Koeffler HP (2011) Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia. Leuk Res 35(10):1345–1349

    CAS  PubMed Central  PubMed  Google Scholar 

  70. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz MJ, Prosper F, Heiniger A, Torres A (2004) Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104(8):2492–2498

    CAS  PubMed  Google Scholar 

  71. Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, Carbone A, Gaidano G (2004) Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 89(2):154–164

    CAS  PubMed  Google Scholar 

  72. Yang Y, Takeuchi S, Hofmann WK, Ikezoe T, van Dongen JJ, Szczepanski T, Bartram CR, Yoshino N, Taguchi H, Koeffler HP (2006) Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk Res 30(1):98–102

    CAS  PubMed  Google Scholar 

  73. Matsushita C, Yang Y, Takeuchi S, Matsushita M, Van Dongen JJ, Szczepanski T, Bartram CR, Seo H, Koeffler HP, Taguchi H (2004) Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep 12(1):97–99

    CAS  PubMed  Google Scholar 

  74. Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, Karp JE, Herman JG, Carraway HE (2010) Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 5(7):590–600

    CAS  PubMed  Google Scholar 

  75. Voso MT, Scardocci A, Guidi F, Zini G, Di Mario A, Pagano L, Hohaus S, Leone G (2004) Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 103(2):698–700

    CAS  PubMed  Google Scholar 

  76. Aggerholm A, Hokland P (2000) DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology? Blood 95(9):2997–2999

    CAS  PubMed  Google Scholar 

  77. Ekmekci CG, Gutierrez MI, Siraj AK, Ozbek U, Bhatia K (2004) Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol 77(3):233–240

    CAS  PubMed  Google Scholar 

  78. Li J, El-Naggar A, Mao L (2005) Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 104(4):771–776

    CAS  PubMed  Google Scholar 

  79. Koga Y, Kitajima Y, Miyoshi A, Sato K, Kitahara K, Soejima H, Miyazaki K (2005) Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers. Ann Surg Oncol 12(5):354–363

    PubMed  Google Scholar 

  80. Tozawa T, Tamura G, Honda T, Nawata S, Kimura W, Makino N, Kawata S, Sugai T, Suto T, Motoyama T (2004) Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci 95(9):736–740

    CAS  PubMed  Google Scholar 

  81. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S, Kuwano M (2002) The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62(14):4048–4053

    CAS  PubMed  Google Scholar 

  82. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF (2001) Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61(24):8659–8663

    CAS  PubMed  Google Scholar 

  83. Gutierrez MI, Siraj AK, Khaled H, Koon N, El-Rifai W, Bhatia K (2004) CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer. Mod Pathol 17(10):1268–1274

    CAS  PubMed  Google Scholar 

  84. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M (2006) Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer 119(6):1396–1402

    CAS  PubMed  Google Scholar 

  85. Chen PC, Tsai MH, Yip SK, Jou YC, Ng CF, Chen Y, Wang X, Huang W, Tung CL, Chen GC, Huang MM, Tong JH, Song EJ, Chang DC, Hsu CD, To KF, Shen CH, Chan MW (2011) Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics 4:45

    CAS  PubMed Central  PubMed  Google Scholar 

  86. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF (2002) Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8(2):464–470

    CAS  PubMed  Google Scholar 

  87. Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, Schostak M, Schrader M (2006) Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer 95(12):1701–1707

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Christoph F, Hinz S, Kempkensteffen C, Weikert S, Krause H, Schostak M, Schrader M, Miller K (2007) A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer. J Cancer Res Clin Oncol 133(6):343–349

    CAS  PubMed  Google Scholar 

  89. Sobti RC, MalekZadeh K, Nikbakht M, Sadeghi IA, Shekari M, Singh SK (2010) Hypermethylation-mediated partial transcriptional silencing of DAP-kinase gene in bladder cancer. Biomarkers 15(2):167–174

    CAS  PubMed  Google Scholar 

  90. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, Huland H, Jones PA, Liang G (2005) Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 41(17):2769–2778

    CAS  PubMed  Google Scholar 

  91. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K (2008) Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 75(3–4):145–151

    CAS  PubMed  Google Scholar 

  92. Van der Auwera I, Bovie C, Svensson C, Limame R, Trinh XB, van Dam P, Van Laere SJ, Van Marck E, Vermeulen PB, Dirix LY (2009) Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes. Cancer Biol Ther 8(23):2252–2259

    PubMed  Google Scholar 

  93. Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limame R, van Dam P, van Laere SJ, van Marck EA, Dirix LY, Vermeulen PB (2010) Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer 10:97

    PubMed Central  PubMed  Google Scholar 

  94. Lehmann U, Celikkaya G, Hasemeier B, Langer F, Kreipe H (2002) Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 62(22):6634–6638

    CAS  PubMed  Google Scholar 

  95. Chu LC, Eberhart CG, Grossman SA, Herman JG (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119(10):2487–2491

    CAS  PubMed  Google Scholar 

  96. Jeong DH, Youm MY, Kim YN, Lee KB, Sung MS, Yoon HK, Kim KT (2006) Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer 16(3):1234–1240

    CAS  PubMed  Google Scholar 

  97. Iliopoulos D, Oikonomou P, Messinis I, Tsezou A (2009) Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression. Oncol Rep 22(1):199–204

    CAS  PubMed  Google Scholar 

  98. Leung RC, Liu SS, Chan KY, Tam KF, Chan KL, Wong LC, Ngan HY (2008) Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer. Oncol Rep 19(5):1339–1345

    CAS  PubMed  Google Scholar 

  99. Yang HJ, Liu VW, Wang Y, Chan KY, Tsang PC, Khoo US, Cheung AN, Ngan HY (2004) Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 93(2):435–440

    CAS  PubMed  Google Scholar 

  100. Kang S, Kim JW, Kang GH, Lee S, Park NH, Song YS, Park SY, Kang SB, Lee HP (2006) Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int J Cancer 118(9):2168–2171

    CAS  PubMed  Google Scholar 

  101. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV (2003) Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2:24

    PubMed Central  PubMed  Google Scholar 

  102. Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6:212

    PubMed Central  PubMed  Google Scholar 

  103. Zhao XL, Meng ZY, Qiao YH, Zhang HL (2008) Promoter methylation of DAPK gene in cervical carcinoma. Ai Zheng 27(9):919–923

    CAS  PubMed  Google Scholar 

  104. Niyazi M, Liu XW, Zhu KC (2012) Death-associated protein kinase promoter (DAPK) hypermethylation in uterine cervical cancer and intraepithelial neoplasia in Uyghur nationality women. Zhonghua Zhong Liu Za Zhi 34(1):31–34

    CAS  PubMed  Google Scholar 

  105. Liu XF, Kong FM, Xu Z, Yu SP, Sun FB, Zhang CS, Huang QX, Zhou XT, Song ZW (2007) Promoter hypermethylation of death-associated protein kinase gene in cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 6(4):407–411

    CAS  PubMed  Google Scholar 

  106. Yang B, House MG, Guo M, Herman JG, Clark DP (2005) Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 18(3):412–420

    CAS  PubMed  Google Scholar 

  107. Lee S, Kim WH, Jung HY, Yang MH, Kang GH (2002) Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 161(3):1015–1022

    CAS  PubMed  Google Scholar 

  108. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C (2007) Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129(5):879–890

    CAS  PubMed  Google Scholar 

  109. Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y, Suzuki H, Yawata A, Kusano M, Fujita M, Hosokawa M, Yanagihara K, Tokino T, Imai K (2002) DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer 86(11):1817–1823

    CAS  PubMed Central  PubMed  Google Scholar 

  110. Schneider-Stock R, Kuester D, Ullrich O, Mittag F, Habold C, Boltze C, Peters B, Krueger S, Hintze C, Meyer F, Hartig R, Roessner A (2006) Close localization of DAP-kinase positive tumour-associated macrophages and apoptotic colorectal cancer cells. J Pathol 209(1):95–105

    CAS  PubMed  Google Scholar 

  111. Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH (2004) Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 84(7):884–893

    CAS  PubMed  Google Scholar 

  112. Lee BB, Lee EJ, Jung EH, Chun HK, Chang DK, Song SY, Park J, Kim DH (2009) Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15(19):6185–6191

    CAS  PubMed  Google Scholar 

  113. Anacleto C, Leopoldino AM, Rossi B, Soares FA, Lopes A, Rocha JC, Caballero O, Camargo AA, Simpson AJ, Pena SD (2005) Colorectal cancer “methylator phenotype”: fact or artifact? Neoplasia 7(4):331–335

    CAS  PubMed Central  PubMed  Google Scholar 

  114. Iacopetta B, Grieu F, Li W, Ruszkiewicz A, Caruso M, Moore J, Watanabe G, Kawakami K (2006) APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. Int J Cancer 119(10):2272–2278

    CAS  PubMed  Google Scholar 

  115. Yamaguchi S, Asao T, Nakamura J, Ide M, Kuwano H (2003) High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett 194(1):99–105

    CAS  PubMed  Google Scholar 

  116. Anacleto C, Rossi B, Lopes A, Soares FA, Rocha JC, Caballero O, Camargo AA, Simpson AJ, Pena SD (2005) Development and application of a multiplex PCR procedure for the detection of DNA methylation in colorectal cancer. Oncol Rep 13(2):325–328

    CAS  PubMed  Google Scholar 

  117. Mittag F, Kuester D, Vieth M, Peters B, Stolte B, Roessner A, Schneider-Stock R (2006) DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett 240(1):69–75

    CAS  PubMed  Google Scholar 

  118. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23(22):4014–4022

    CAS  PubMed Central  PubMed  Google Scholar 

  119. Nakamichi I, Tomita Y, Zhang B, Sugiyama H, Kanakura Y, Fukuhara S, Hino M, Kanamaru A, Ogawa H, Aozasa K (2007) Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann Hematol 86(8):557–564

    CAS  PubMed  Google Scholar 

  120. Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S (2008) Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol 19(10):1774–1786

    CAS  PubMed  Google Scholar 

  121. Nakatsuka S, Takakuwa T, Tomita Y, Hoshida Y, Nishiu M, Yamaguchi M, Nishii K, Yang WI, Aozasa K (2003) Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies. Cancer Sci 94(1):87–91

    CAS  PubMed  Google Scholar 

  122. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG (2003) Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9(8):2912–2919

    CAS  PubMed  Google Scholar 

  123. Li B, Wang B, Niu LJ, Jiang L, Qiu CC (2011) Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics 6(3):307–316

    CAS  PubMed  Google Scholar 

  124. Kuester D, Dar AA, Moskaluk CC, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, El-Rifai W, Schneider-Stock R (2007) Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett’s esophageal adenocarcinoma and its association with clinical progression. Neoplasia 9(3):236–245

    CAS  PubMed Central  PubMed  Google Scholar 

  125. Schildhaus HU, Krockel I, Lippert H, Malfertheiner P, Roessner A, Schneider-Stock R (2005) Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol 26(6):1493–1500

    CAS  PubMed  Google Scholar 

  126. Voso MT, Gumiero D, D’Alo F, Guidi F, Mansueto G, Di Febo AL, Massini G, Martini M, Larocca LM, Hohaus S, Leone G (2006) DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. Haematologica 91(9):1252–1256

    CAS  PubMed  Google Scholar 

  127. Krajnovic M, Radojkovic M, Davidovic R, Dimitrijevic B, Krtolica K (2013) Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma. Med Oncol 30(1):441

    PubMed  Google Scholar 

  128. Kim HC, Kim JC, Roh SA, Yu CS, Yook JH, Oh ST, Kim BS, Park KC, Chang R (2005) Aberrant CpG island methylation in early-onset sporadic gastric carcinoma. J Cancer Res Clin Oncol 131(11):733–740

    CAS  PubMed  Google Scholar 

  129. To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, Ng EK, Chung SC, Sung JJ (2002) Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 102(6):623–628

    CAS  PubMed  Google Scholar 

  130. Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, Yamada H, Kojima K, Sugihara K (2008) Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 122(3):603–608

    CAS  PubMed  Google Scholar 

  131. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG (2001) CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 61(7):2847–2851

    CAS  PubMed  Google Scholar 

  132. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF (2002) Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8(6):1761–1766

    CAS  PubMed  Google Scholar 

  133. Tang LP, Cho CH, Hui WM, Huang C, Chu KM, Xia HH, Lam SK, Rashid A, Wong BC, Chan AO (2006) An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion 74(2):85–90

    CAS  PubMed  Google Scholar 

  134. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, Yonemura J, Maeda Y, Maruyama N, Kamano T, Kamiya Y, Fujita H, Nakagawa Y, Nagasaka M, Iwata M, Hirata I, Arisawa T (2010) Association between cyclin D1 polymorphism with CpG island promoter methylation status of tumor suppressor genes in gastric cancer. Dig Dis Sci 55(12):3449–3457

    CAS  PubMed  Google Scholar 

  135. Ksiaa F, Ziadi S, Amara K, Korbi S, Trimeche M (2009) Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. Clin Chim Acta 404(2):128–133

    CAS  PubMed  Google Scholar 

  136. Ye M, Li D, Zhou F, Guo Q, Xia B (2012) Epigenetic regulation of death-associated protein kinase expression in primary gastric cancers from Chinese patients. Eur J Cancer Prev 21(3):241–246

    CAS  PubMed  Google Scholar 

  137. Ben Ayed-Guerfali D, Benhaj K, Khabir A, Abid M, Bayrouti MI, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R (2011) Hypermethylation of tumor-related genes in Tunisian patients with gastric carcinoma: clinical and biological significance. J Surg Oncol 103(7):687–694

    CAS  PubMed  Google Scholar 

  138. Chan AW, Chan MW, Lee TL, Ng EK, Leung WK, Lau JY, Tong JH, Chan FK, To KF (2005) Promoter hypermethylation of death-associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13(5):937–941

    CAS  PubMed  Google Scholar 

  139. Gao Y, Guan M, Su B, Liu W, Xu M, Lu Y (2004) Hypermethylation of the RASSF1A gene in gliomas. Clin Chim Acta 349(1–2):173–179

    CAS  PubMed  Google Scholar 

  140. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT (2002) Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21(27):4231–4236

    CAS  PubMed  Google Scholar 

  141. Nayak CS, Carvalho AL, Jeronimo C, Henrique R, Kim MM, Hoque MO, Chang S, Jiang WW, Koch W, Westra W, Sidransky D, Califano J (2007) Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Laryngoscope 117(8):1376–1380

    CAS  PubMed  Google Scholar 

  142. Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, El-Naggar AK (2004) Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res 10(11):3825–3830

    CAS  PubMed  Google Scholar 

  143. Martone T, Gillio-Tos A, De Marco L, Fiano V, Maule M, Cavalot A, Garzaro M, Merletti F, Cortesina G (2007) Association between hypermethylated tumor and paired surgical margins in head and neck squamous cell carcinomas. Clin Cancer Res 13(17):5089–5094

    CAS  PubMed  Google Scholar 

  144. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60(4):892–895

    CAS  PubMed  Google Scholar 

  145. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D (2001) Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61(3):939–942

    CAS  PubMed  Google Scholar 

  146. Lehmann U, Berg-Ribbe I, Wingen LU, Brakensiek K, Becker T, Klempnauer J, Schlegelberger B, Kreipe H, Flemming P (2005) Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res 11(10):3654–3660

    CAS  PubMed  Google Scholar 

  147. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A (2007) Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer 97(9):1260–1265

    CAS  PubMed Central  PubMed  Google Scholar 

  148. Harder J, Opitz OG, Brabender J, Olschewski M, Blum HE, Nomoto S, Usadel H (2008) Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. Int J Cancer 122(12):2800–2804

    CAS  PubMed  Google Scholar 

  149. Dikshit RP, Gillio-Tos A, Brennan P, De Marco L, Fiano V, Martinez-Penuela JM, Boffetta P, Merletti F (2007) Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. Cancer 110(8):1745–1751

    CAS  PubMed  Google Scholar 

  150. Kong WJ, Zhang S, Guo C, Wang Y, Zhang D (2005) Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer. Laryngoscope 115(8):1395–1401

    CAS  PubMed  Google Scholar 

  151. Paluszczak J, Misiak P, Wierzbicka M, Wozniak A, Baer-Dubowska W (2011) Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. Oral Oncol 47(2):104–107

    CAS  PubMed  Google Scholar 

  152. Niklinska W, Naumnik W, Sulewska A, Kozlowski M, Pankiewicz W, Milewski R (2009) Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem Cytobiol 47(2):275–280

    CAS  PubMed  Google Scholar 

  153. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z (2008) Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 112(6):1325–1336

    CAS  PubMed  Google Scholar 

  154. Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, Kelsey KT (2001) Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20(14):1765–1770

    CAS  PubMed  Google Scholar 

  155. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61(1):249–255

    CAS  PubMed  Google Scholar 

  156. Safar AM, Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, Hutchins LF, Fan CY (2005) Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 11(12):4400–4405

    CAS  PubMed  Google Scholar 

  157. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T (2003) Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 94(7):589–592

    CAS  PubMed  Google Scholar 

  158. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF (2007) Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247(1):56–71

    CAS  PubMed Central  PubMed  Google Scholar 

  159. Kim YT, Lee SH, Sung SW, Kim JH (2005) Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Ann Thorac Surg 79(4):1180–1188 Discussion 1180–1188

    PubMed  Google Scholar 

  160. Vallbohmer D, Brabender J, Yang D, Schneider PM, Metzger R, Danenberg KD, Holscher AH, Danenberg PV (2006) DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer 8(1):39–44

    CAS  PubMed  Google Scholar 

  161. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T (2007) Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58(1):131–138

    PubMed  Google Scholar 

  162. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92(18):1511–1516

    CAS  PubMed  Google Scholar 

  163. Rastetter M, Schagdarsurengin U, Lahtz C, Fiedler E, Marsch W, Dammann R, Helmbold P (2007) Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol Histopathol 22(9):1005–1015

    CAS  PubMed  Google Scholar 

  164. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C, Lahm H (2006) Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 54(1):109–116

    PubMed  Google Scholar 

  165. Chim CS, Liang R, Leung MH, Kwong YL (2007) Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol 60(1):104–106

    CAS  PubMed  Google Scholar 

  166. Chim CS, Liang R, Fung TK, Choi CL, Kwong YL (2007) Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol 60(6):664–669

    CAS  PubMed  Google Scholar 

  167. Ng MH, To KW, Lo KW, Chan S, Tsang KS, Cheng SH, Ng HK (2001) Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 7(6):1724–1729

    CAS  PubMed  Google Scholar 

  168. Yuregir OO, Yurtcu E, Kizilkilic E, Kocer NE, Ozdogu H, Sahin FI (2010) Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients. Int J Lab Hematol 32(2):142–149

    PubMed  Google Scholar 

  169. Braggio E, Maiolino A, Gouveia ME, Magalhaes R, Souto Filho JT, Garnica M, Nucci M, Renault IZ (2010) Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol 91(1):87–96

    CAS  PubMed  Google Scholar 

  170. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP (2002) Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8(1):131–137

    CAS  PubMed  Google Scholar 

  171. Wong TS, Chang HW, Tang KC, Wei WI, Kwong DL, Sham JS, Yuen AP, Kwong YL (2002) High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin Cancer Res 8(2):433–437

    CAS  PubMed  Google Scholar 

  172. Fendri A, Masmoudi A, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad-Gargouri R (2009) Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol Ther 8(5):444–451

    CAS  PubMed  Google Scholar 

  173. Kong WJ, Zhang S, Guo CK, Wang YJ, Chen X, Zhang SL, Zhang D, Liu Z, Kong W (2006) Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma. Anticancer Drugs 17(3):251–259

    CAS  PubMed  Google Scholar 

  174. Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M (2012) Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clin Chim Acta 413(7–8):795–802

    CAS  PubMed  Google Scholar 

  175. Gonzalez-Gomez P, Bello MJ, Arjona D, Alonso ME, Lomas J, De Campos JM, Kusak ME, Gutierrez M, Sarasa JL, Rey JA (2003) Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas. Oncol Rep 10(5):1519–1523

    CAS  PubMed  Google Scholar 

  176. Choung HK, Kim YA, Lee MJ, Kim N, Khwarg SI (2012) Multigene methylation analysis of ocular adnexal MALT lymphoma and their relationship to Chlamydophila psittaci infection and clinical characteristics in South Korea. Invest Ophthalmol Vis Sci 53(4):1928–1935

    CAS  PubMed  Google Scholar 

  177. Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, Kambara T, Shirakawa Y, Naomoto Y, Ouchida M, Shimizu K, Tanaka N, Jass JR, Matsubara N (2007) Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 56(1):13–19

    CAS  PubMed  Google Scholar 

  178. Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, Sonoda T, Kohama G, Tokino T (2002) Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 8(10):3164–3171

    CAS  PubMed  Google Scholar 

  179. Liu Y, Zhou ZT, He QB, Jiang WW (2012) DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients. Med Oncol 29(2):729–733

    CAS  PubMed  Google Scholar 

  180. Supic G, Kozomara R, Brankovic-Magic M, Jovic N, Magic Z (2009) Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol 45(12):1051–1057

    CAS  PubMed  Google Scholar 

  181. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65(19):8961–8967

    CAS  PubMed  Google Scholar 

  182. Hafner N, Diebolder H, Jansen L, Hoppe I, Durst M, Runnebaum IB (2011) Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer. Gynecol Oncol 121(1):224–229

    PubMed  Google Scholar 

  183. Collins Y, Dicioccio R, Keitz B, Lele S, Odunsi K (2006) Methylation of death-associated protein kinase in ovarian carcinomas. Int J Gynecol Cancer 16(Suppl 1):195–199

    PubMed  Google Scholar 

  184. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S, Hirohashi S (2006) DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 27(6):1160–1168

    CAS  PubMed  Google Scholar 

  185. Dansranjavin T, Mobius C, Tannapfel A, Bartels M, Wittekind C, Hauss J, Witzigmann H (2006) E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. Oncol Rep 15(5):1125–1131

    CAS  PubMed  Google Scholar 

  186. Yamanaka M, Watanabe M, Yamada Y, Takagi A, Murata T, Takahashi H, Suzuki H, Ito H, Tsukino H, Katoh T, Sugimura Y, Shiraishi T (2003) Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 106(3):382–387

    CAS  PubMed  Google Scholar 

  187. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8(2):514–519

    CAS  PubMed  Google Scholar 

  188. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64(6):1975–1986

    CAS  PubMed  Google Scholar 

  189. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, Cooper WN, Lee J, Gentle D, Macdonald F, Kishida T, Grundy R, Yao M, Latif F, Maher ER (2003) Multigene methylation analysis of Wilms’ tumour and adult renal cell carcinoma. Oncogene 22(43):6794–6801

    CAS  PubMed  Google Scholar 

  190. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Kollermann J, Miller K, Schrader M (2006) Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res 12(17):5040–5046

    CAS  PubMed  Google Scholar 

  191. Ahmad ST, Arjumand W, Seth A, Saini AK, Sultana S (2012) Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumour Biol 33(2):395–402

    CAS  PubMed  Google Scholar 

  192. Sato H, Oka T, Shinnou Y, Kondo T, Washio K, Takano M, Takata K, Morito T, Huang X, Tamura M, Kitamura Y, Ohara N, Ouchida M, Ohshima K, Shimizu K, Tanimoto M, Takahashi K, Matsuoka M, Utsunomiya A, Yoshino T (2010) Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol 176(1):402–415

    CAS  PubMed  Google Scholar 

  193. Brait M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papagerakis S, Zahurak M, Goodman SM, Zeiger M, Sidransky D, Umbricht CB, Hoque MO (2012) Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer. Epigenetics 7(7):710–719

    CAS  PubMed  Google Scholar 

  194. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R (2006) CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16(7):633–642

    CAS  PubMed  Google Scholar 

  195. Su Y, Xu H, Xu Y, Yu J, Xian Y, Luo Q (2012) Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes. Hematology 17(1):41–46

    CAS  PubMed  Google Scholar 

  196. Ling YH, Aracil M, Zou Y, Yuan Z, Lu B, Jimeno J, Cuervo AM, Perez-Soler R (2011) PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clin Cancer Res 17(16):5353–5366

    CAS  PubMed  Google Scholar 

  197. Luo XJ, Li LL, Deng QP, Yu XF, Yang LF, Luo FJ, Xiao LB, Chen XY, Ye M, Liu JK, Cao Y (2011) Grifolin, a potent antitumour natural product upregulates death-associated protein kinase 1 DAPK1 via p53 in nasopharyngeal carcinoma cells. Eur J Cancer 47(2):316–325

    CAS  PubMed  Google Scholar 

  198. Zhang H, Chen GG, Zhang Z, Chun S, Leung BC, Lai PB (2012) Induction of autophagy in hepatocellular carcinoma cells by SB203580 requires activation of AMPK and DAPK but not p38 MAPK. Apoptosis 17(4):325–334

    CAS  PubMed  Google Scholar 

  199. Shin H, Lee YS, Lee YC (2012) Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells. Oncol Rep 27(4):1111–1115

    CAS  PubMed  Google Scholar 

  200. Zhang HT, Feng ZL, Wu J, Wang YJ, Guo X, Liang NC, Zhu ZY, Ma JQ (2007) Sodium butyrate-induced death-associated protein kinase expression promote Raji cell morphological change and apoptosis by reducing FAK protein levels. Acta Pharmacol Sin 28(11):1783–1790

    CAS  PubMed  Google Scholar 

  201. Jiang Q, Li F, Shi K, Yang Y, Xu C (2012) Sodium selenite-induced activation of DAPK promotes autophagy in human leukemia HL60 cells. BMB Rep 45(3):194–199

    CAS  PubMed  Google Scholar 

  202. Wu J, Hu CP, Gu QH, Li YP, Song M (2010) Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharmacol Sin 31(1):93–101

    PubMed  Google Scholar 

  203. Ivanovska J, Tregubova A, Mahadevan V, Chakilam S, Gandesiri M, Benderska N, Ettle B, Hartmann A, Soder S, Ziesche E, Fischer T, Lautscham L, Fabry B, Segerer G, Gohla A, Schneider-Stock R (2013) Identification of DAPK as a scaffold protein for the LIMK/cofilin complex in TNF-induced apoptosis. Int J Biochem Cell Biol 45(8):1720–1729

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Professor Duncan Jodrell (Oncology Department, University of Cambridge) for his critical review of the manuscript. This work was supported by the Specialized Research Fund for the Doctoral Program of Higher Education (20103503120002) and the Foundation of Fujian Educational Committee (JA12061).

Author information

Authors and Affiliations

  1. Fujian Key Laboratory of Developmental and Neural Biology, College of Life Sciences, Fujian Normal University, Fuzhou, 350108, Fujian, People’s Republic of China

    Yide Huang, Ling Chen, Libin Guo & Yao Lin

  2. Institute of Genetics and Molecular Medicine, Cell Signalling Unit, University of Edinburgh, Edinburgh, EH4 2XR, UK

    Ted R. Hupp

Authors
  1. Yide Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ling Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Libin Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ted R. Hupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yao Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yao Lin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, Y., Chen, L., Guo, L. et al. Evaluating DAPK as a therapeutic target. Apoptosis 19, 371–386 (2014). https://doi.org/10.1007/s10495-013-0919-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-013-0919-2

Keywords

Search

Navigation